Ophthalmopathy and hyperthyroidism. A comparison between patients receiving different antithyroid treatments

Area of Science:

• Ophthalmology
• Endocrinology
• Thyroid Disease Management

Background:

• Thyrotoxicosis, a condition of excess thyroid hormones, is frequently associated with ocular complications.
• Thyroid eye disease (TED) or Graves' ophthalmopathy is a common manifestation of thyrotoxicosis.
• Understanding the impact of different treatment modalities on TED progression is crucial for patient management.

Purpose of the Study:

• To compare the incidence and development of ophthalmopathy in patients with thyrotoxicosis undergoing different treatment regimens.
• To assess long-term ocular outcomes across medical, radioiodine, and surgical treatment groups.

Main Methods:

• A cohort of 125 thyrotoxic patients was observed over a 6-20 year period.
• Patients were categorized into three treatment groups: medical (n=72), radioiodine (n=36), and surgical (n=17).
• Ophthalmopathy development and severity were evaluated and compared among the groups.

Main Results:

• The degree of ophthalmopathy was found to be similar across all three treatment groups.
• No statistically significant differences were observed in the development or progression of ophthalmopathy based on the treatment received.
• Long-term follow-up revealed comparable ocular outcomes irrespective of whether patients received medical, radioiodine, or surgical treatment for thyrotoxicosis.

Conclusions:

• Treatment modality for thyrotoxicosis does not significantly influence the development or severity of associated ophthalmopathy.
• Ophthalmopathy in thyrotoxic patients progresses similarly regardless of medical, radioiodine, or surgical intervention.
• These findings suggest that ophthalmopathy management in thyrotoxicosis should be considered independently of the chosen primary treatment for the thyroid condition.